Comparative Bioavailability and Effect of Food on CMX001 in Healthy Volunteers

This study has been completed.
National Institutes of Health (NIH)
Information provided by:
Chimerix Identifier:
First received: October 23, 2008
Last updated: February 1, 2010
Last verified: February 2010
The purpose of this study is to compare the bioavailability of CMX001 when administered as a tablet vs a solution and to determine the effect of a high-fat meal on CMX001 bioavailability.

Condition Intervention Phase
Drug: CMX001
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Bio-availability Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Open-Label, Randomized, 3-Way Crossover, Single-Dose Study in Healthy Volunteers Comparing the Bioavailability of CMX001 (HDP-Cidofovir Conjugate) Delivered as a Tablet Formulation vs a Solution Formulation and the Effect of Food on CMX001 Bioavailability

Further study details as provided by Chimerix:

Primary Outcome Measures:
  • AUC and Cmax of CMX001 and cidofovir [ Time Frame: Each of 3 doses ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Clinical and laboratory endpoints and adverse events [ Time Frame: Throughout the study ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 24
Study Start Date: October 2008
Study Completion Date: January 2009
Primary Completion Date: December 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
All subjects will receive three 40mg doses of CMX001 as 1)solution fasted, 2)tablet fasted and 3)tablet following a high-fat breakfast. The order in which each subject receives each of the doses will be determined by a randomization code.
Drug: CMX001
CMX001 tablet fasted, CMX001 tablet fed, CMX001 solution fasted


Ages Eligible for Study:   18 Years to 55 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Healthy males and non-childbearing females 18-55 years old

Exclusion Criteria:

  • Use of an investigational drug and/or treatment within 30 days prior to enrollment.
  • Positive HIV, Hepatitis B or Hepatitis C test result
  • Tobacco user
  • History of GI disease or disorder
  • History of positive fecal occult blood test (FOBT)
  • Body Mass Index (BMI) > 30 or < 18, or body weight < 50 kg
  • Prior abdominal or pelvic surgery
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00780182

United States, North Carolina
AAI Pharma
Rtp, North Carolina, United States, 27709
Sponsors and Collaborators
National Institutes of Health (NIH)
Principal Investigator: Evin H Sides, III, MD AAIPharma
  More Information

Responsible Party: Neil Frazer/ Chief Medical Officer, Chimerix Identifier: NCT00780182     History of Changes
Other Study ID Numbers: CMX001-103  DMID-08-0020 
Study First Received: October 23, 2008
Last Updated: February 1, 2010
Health Authority: United States: Food and Drug Administration

Keywords provided by Chimerix:
Bioavailability processed this record on May 23, 2016